iECURE, Inc

iECURE, Inc., based in Blue Bell, PA, is dedicated to developing long-lasting curative medicines for patients suffering from devastating genetic disorders. The company focuses on innovative in vivo gene editing techniques, collaborating with the University of Pennsylvania's Gene Therapy Program to address rare monogenic liver diseases.

With a management team comprised of genetic medicine experts and a proven track record in biotechnology, iECURE aims to reverse the course of genetic conditions through its mutation-agnostic gene insertion methods. Their current initiatives are primarily centered on liver disorders caused by dysfunctional genes, striving to provide stable, healthy gene expression for affected patients.

Generated from the website